{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:46:44Z","timestamp":1784803604382,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LTGY23H160007"],"award-info":[{"award-number":["LTGY23H160007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113391","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T08:07:36Z","timestamp":1729325256000},"page":"113391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases"],"prefix":"10.1016","volume":"143","author":[{"given":"Kaibo","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dujiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7187-8804","authenticated-orcid":false,"given":"Yanjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113391_b0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.intimp.2024.113391_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194779","article-title":"MET in non-small-cell lung cancer (NSCLC): Cross 'a long and winding road' looking for a target","volume":"15","author":"Spitaleri","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2024.113391_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0025","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113391_b0030","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0040","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0045","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","article-title":"MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2024.113391_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221128414","article-title":"Optimal treatments for NSCLC patients harboring primary or acquired MET amplification","volume":"21","author":"Sun","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2024.113391_b0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cllc.2016.09.011","article-title":"MET gene amplification and overexpression in chinese non-small-cell lung cancer patients without EGFR mutations","volume":"18","author":"Song","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.intimp.2024.113391_b0060","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113391_b0065","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.21037\/atm-21-4543","article-title":"Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"9","author":"Su","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.intimp.2024.113391_b0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2020.01.005","article-title":"Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer","volume":"141","author":"Yoshimura","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2024.113391_b0075","article-title":"MET amplification and efficacy of nivolumab in patients with NSCLC","volume":"2","author":"Yoshimura","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.intimp.2024.113391_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00262-021-02964-x","article-title":"Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC","volume":"71","author":"Wang","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2024.113391_b0085","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2024.113391_b0090","doi-asserted-by":"crossref","unstructured":"S.S. Maher Albitar, Wanlong Ma, Shiping Jiang Wayne Chen, Vincent Funari, Forrest Blocker and Sally Agersborg, Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer 9 (2018) 13682\u201313693.","DOI":"10.18632\/oncotarget.24455"},{"key":"10.1016\/j.intimp.2024.113391_b0095","doi-asserted-by":"crossref","unstructured":"Marta Dom\u00e8nech, A.M.M.O.M., Jose Luis Mate, Anna Estival, Teresa Moran, Marc Cucurull, Maria Saigi, Ainhoa Hernandez, Carolina Sanz, Alba Hernandez-Gallego, Aintzane Urbizu, Anna Martinez-Cardus, Adri\u00e0 Bernat and Enric Carcereny, Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver, Oncotarget 12 (2021) 1802\u20131810.","DOI":"10.18632\/oncotarget.28045"},{"key":"10.1016\/j.intimp.2024.113391_b0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41416-020-0888-5","article-title":"Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy","volume":"123","author":"Niemeijer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2024.113391_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2024.113391_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20174287","article-title":"MET receptor tyrosine kinase regulates the expression of co-stimulatory and co-inhibitory molecules in tumor cells and contributes to PD-L1-mediated suppression of immune cell function","volume":"20","author":"Ahn","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113391_b0115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113391_b0120","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2024.113391_b0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41416-018-0315-3","article-title":"Met inhibition revokes IFNgamma-induction of PD-1 ligands in MET-amplified tumours","volume":"120","author":"Martin","year":"2019","journal-title":"Br. J. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:31:39Z","timestamp":1736303499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924019131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"alternative-id":["S1567576924019131"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113391","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113391"}}